Clinical Trials
9 trialsNCT05308446 2026-06-03
Testing the Addition of Nivolumab to Standard Treatment for Patients With Metastatic or Unresectable Colorectal Cancer That Have a BRAF Mutation
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT06997497 2026-05-29
KANDLELIT-012
Merck Sharp & Dohme LLC
Phase 3 Recruiting
NCT06607185 2026-05-26
A Study of the Pan-KRAS Inhibitor LY4066434 in Participants With KRAS Mutant Solid Tumors
Eli Lilly and Company
Phase 1 Active not recruiting
NCT04017650 2026-05-22
Encorafenib, Cetuximab, and Nivolumab in Treating Patients With Microsatellite Stable, BRAFV600E Mutated Unresectable or Metastatic Colorectal Cancer
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT06704724 2026-05-22
A Study to Learn About the Study Medicine PF-07985045 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Change in a Gene.
Pfizer
Phase 1 Terminated
NCT04793958 2026-04-27
KRYSTAL-10
Mirati Therapeutics Inc.
Phase 3 Active not recruiting
NCT07549399 2026-04-24
CRITâ…¡
Sixth Affiliated Hospital, Sun Yat-sen University
Phase 3 Not yet recruiting
NCT06447662 2026-04-20
A Study to Learn About the Study Medicine PF-07934040 When Given Alone or With Other Anti-cancer Therapies in People With Advanced Solid Tumors That Have a Genetic Mutation.
Pfizer
Phase 1 Recruiting
NCT05217446 2026-04-07
SEAMARK
Pfizer
Phase 2 Active not recruiting